Cooper Companies (NASDAQ:COO) Stock Price Expected to Rise, Barclays Analyst Says

Cooper Companies (NASDAQ:COO) had its price objective boosted by equities researchers at Barclays from $98.00 to $103.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Barclays‘s price objective indicates a potential upside of 34.55% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings raised Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. Morgan Stanley upped their target price on shares of Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Monday, December 8th. The Goldman Sachs Group reissued a “sell” rating and set a $73.00 price target on shares of Cooper Companies in a research report on Friday, January 9th. Piper Sandler reissued an “overweight” rating and set a $94.00 price objective (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Needham & Company LLC upped their price objective on shares of Cooper Companies from $99.00 to $101.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average target price of $90.79.

Cooper Companies Stock Performance

Shares of COO opened at $76.55 on Friday. The company has a 50-day simple moving average of $82.11 and a two-hundred day simple moving average of $75.98. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The firm has a market capitalization of $14.94 billion, a PE ratio of 37.90, a price-to-earnings-growth ratio of 2.19 and a beta of 1.02. Cooper Companies has a one year low of $61.78 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.07. Cooper Companies had a return on equity of 10.36% and a net margin of 9.67%.The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the business earned $0.92 EPS. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. On average, analysts anticipate that Cooper Companies will post 3.98 EPS for the current fiscal year.

Insider Transactions at Cooper Companies

In related news, Director Cynthia L. Lucchese purchased 1,784 shares of the stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of $84.06 per share, with a total value of $149,963.04. Following the transaction, the director directly owned 9,445 shares in the company, valued at $793,946.70. This trade represents a 23.29% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Maria Rivas acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the completion of the transaction, the director directly owned 11,141 shares in the company, valued at $915,010.33. The trade was a 9.86% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 16,014 shares of company stock worth $1,304,416 over the last quarter. Corporate insiders own 2.08% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently made changes to their positions in COO. New York Life Investment Management LLC lifted its position in Cooper Companies by 0.6% in the 4th quarter. New York Life Investment Management LLC now owns 27,344 shares of the medical device company’s stock valued at $2,241,000 after acquiring an additional 158 shares in the last quarter. Root Financial Partners LLC raised its stake in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the last quarter. Allworth Financial LP boosted its position in shares of Cooper Companies by 14.1% during the fourth quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock valued at $111,000 after buying an additional 167 shares during the last quarter. Wealth Alliance LLC boosted its position in shares of Cooper Companies by 4.2% during the second quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after buying an additional 171 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. increased its holdings in Cooper Companies by 1.3% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock worth $961,000 after buying an additional 175 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.